Goodman served as chair of the FDA Psychopharmacology Drug Advisory Committee (PDAC) from 2004 to 2008. During that time period, the FDA deliberated and eventually decided to require a Black Box warning on suicidality for all antidepressant drugs.[20] Goodman voted in favor of the Black Box warning for the pediatric population in 2004.[21] Two years later, he voted that the warning be extended up to age 24.